Sugi Predict

Sugi Predict / Compounds / SCHEMBL371970

SCHEMBL371970

SCHEMBL371970

COc1cc2nccc(Oc3cc(Cl)c(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c2cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 13/20 0.78
▸ MET P08581 10/20 0.78
▸ KDR P35968 4/20 0.78
▸ MERTK Q12866 6/20 0.73
▸ FLT1 P17948 3/20 0.73
▸ AURKB Q96GD4 3/20 0.73
▸ RET P07949 2/20 0.73
▸ KIT P10721 2/20 0.73
▸ FLT3 P36888 2/20 0.73
▸ AURKA O14965 1/20 0.73
▸ RIPK2 O43353 1/20 0.73
▸ ABCB11 O95342 1/20 0.73
▸ ABL1 P00519 1/20 0.73
▸ EGFR P00533 1/20 0.73
▸ ERBB2 P04626 1/20 0.73
▸ NTRK1 P04629 1/20 0.73
▸ LCK P06239 1/20 0.73
▸ PGR P06401 1/20 0.73
▸ LYN P07948 1/20 0.73
▸ CHRM2 P08172 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693442 1.00 AXL (0.78) AXLMETKDRMERTKFLT1
SCHEMBL29693433 0.93 AXL (0.73) AXLMETKDRMERTKFLT1
SCHEMBL371837 0.93 AXL (0.73) AXLMETKDRMERTKFLT1
SCHEMBL29693478 0.92 AXL (0.82) AXLMETKDRMERTKFLT1
SCHEMBL371830 0.92 AXL (0.82) AXLMETKDRMERTKFLT1
SCHEMBL29693416 0.91 AXL (0.79) AXLMETKDRMERTKFLT1
SCHEMBL372398 0.91 AXL (0.79) AXLMETKDRMERTKFLT1
SCHEMBL19372942 0.89 MET (0.76) AXLMETKDRMERTKFLT1
Exelixis SCHEMBL371899 0.88 MET (1.00) AXLMETKDRMERTKFLT1
Exelixis SCHEMBL29693473 0.88 MET (1.00) AXLMETKDRMERTKFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885KDR 5/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885KDR 5/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS AXL 769/4885MET 312/4885KDR 1023/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885KDR 5/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885KDR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.